Compare ELOG & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELOG | KPRX |
|---|---|---|
| Founded | 2006 | 1998 |
| Country | China | United States |
| Employees | N/A | 13 |
| Industry | Integrated Freight & Logistics | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 11.7M |
| IPO Year | N/A | N/A |
| Metric | ELOG | KPRX |
|---|---|---|
| Price | $0.81 | $2.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 5.5K | ★ 20.6K |
| Earning Date | 07-17-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $1.76 |
| 52 Week High | $3.07 | $2.99 |
| Indicator | ELOG | KPRX |
|---|---|---|
| Relative Strength Index (RSI) | 37.40 | 50.91 |
| Support Level | N/A | $2.44 |
| Resistance Level | $1.00 | $2.61 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 0.00 | 82.35 |
Eastern International Ltd is a holding company. The company operates through its subsidiary engaged in domestic and cross-border professional logistic services including project logistics and general logistics for company clients. Its project logistic services include Construction project logistics and special cargo logistics for large or precision equipment and General logistic services refer to the transportation, warehousing, loading and unloading, and distribution of ordinary products.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.